There are a number of nonpainful treatment options available to treat CL in young children. Miltefosine is the only therapy investigated in a purely paediatric population, and it has been shown to be noninferior and possibly superior to antimony treatment. Topical paromomycin has been shown to be more effective than placebo. Both can be administered without the need for costly inpatient admission and both are more suitable than intralesional antimony, which can be very painful. Both of these treatment options are currently unlicensed in the U.K. for the treatment of cutaneous leishmaniasis.